- Services & Solutions
- Clients & Partners
SRI International Executives Lead Seminar on Collaborative Drug Discovery and Development at BioJapan 2007
MENLO PARK, Calif. – September 12, 2007 – SRI International, an independent nonprofit research and development organization, today announced it is hosting a luncheon seminar on collaborative drug discovery and development at BioJapan 2007. The seminar will take place in the Pacifico Yokohama Convention Center in Yokohama, Japan on Thursday, September 20 from 12:00 pm - 1:00 pm.
Dr. Nathan Collins, Ph.D., executive director of SRI's Biosciences Division, will highlight SRI's drug discovery and preclinical development capabilities. Dr. Collins will share SRI's long and successful record of advancing drugs into the clinic by collaborating with commercial and government partners in all stages of preclinical research and development. He will share how SRI's experienced team delivers quality and value that help partners leverage their R&D investments and focus on their core business.
Featured guest presenter, Mr. Tsuneo Hidaka, founder and former chief of the Pentax Incubation Center will provide a unique overview of Pentax's product innovation strategy and share why the company is working with SRI as a strategic innovation partner. In related news, SRI also announced today it is developing biomarkers with Pentax for oncology diagnostics. Dr. Osamu Karatsu, Ph.D., executive director of SRI Japan will moderate the discussion.
SRI is a top preclinical contractor to the U.S. National Institutes of Health (NIH) and an industry leader in streamlining drug discovery and development. SRI has also pioneered novel partnerships with industry and academia to improve the drug development process.
SRI representatives will be available to discuss SRI innovations and drug discovery programs in booth # 2-19. For more information or to register for the seminar, please contact
biosciences [at] sri.com
In additional related news, SRI also announced today that company executives will present the company’s groundbreaking discipline of innovation methodology at the Innovation Japan event in Tokyo on September 12-14.
About SRI's Biosciences Division
SRI International’s Biosciences Division is an organization of approximately 200 people with all the resources necessary to take biological and chemical research programs from "idea to IND"™ -- from initial discovery to investigational new drug applications to start human clinical trials. SRI Biosciences conducts basic research like a university, performs drug discovery and develops biologics like a biotechnology company, and is a contract research organization (CRO) that offers a full range of preclinical development and pharmaceutical sciences services. SRI Biosciences specializes in cancer, immunology and inflammation, infectious disease, and neurosciences research.
To date, SRI has developed nine drugs internally that have entered clinical trials, with several more currently undergoing preclinical evaluation. Marketed examples of these drugs include Targretin® (bexarotene) and Halfan® (halofantrine). Working with government and industry partners, SRI has helped advance about 150 drugs into clinical trials, and more than 10 drugs onto the market. Through collaborations with other divisions at SRI, Biosciences is also working at the interfaces of science to create technical platforms for the next generation of drug discovery and development in areas such as drug delivery, devices, diagnostics, and systems biology.
About SRI International
Silicon Valley-based SRI International (www.sri.com) is one of the world’s leading independent research and technology development organizations. Founded as Stanford Research Institute in 1946, SRI has been meeting the strategic needs of clients for more than 60 years. The nonprofit research institute performs client-sponsored research and development for government agencies, commercial businesses, and private foundations. In addition to conducting contract R&D, SRI licenses its technologies, forms strategic partnerships, and creates spin-off companies.